Fulgent Genetics has acquired Bako Diagnostics for an undisclosed amount, marking a strategic expansion in the diagnostic services sector. Bako Diagnostics is a specialized provider of diagnostic and therapeutic services, uniquely focused on the pathology of the lower extremity. Its comprehensive offerings include ENFD Analysis, Mass Spectrometry for rapid bacterial identification, and Molecular Genetics for detecting microorganisms and aiding in specific pathologic diagnoses. Fulgent Genetics, a leading provider of genetic testing services, aims to broaden its diagnostic portfolio through this acquisition.
The strategic rationale behind this purchase is rooted in Bako’s deep expertise and market presence. Bako Diagnostics has cultivated an extensive network, providing in-network services to over 200 million covered lives across all five national health plans. This broad insurance coverage and established client base offer Fulgent Genetics immediate access to a wider market and new clinical channels, particularly within the podiatric profession where Bako has been a principal source of educational sponsorship for nearly a decade.
Expected synergies from this acquisition include the integration of Bako’s specialized pathology and therapeutic insights with Fulgent’s advanced genetic testing capabilities. This combination is anticipated to create a more comprehensive diagnostic platform, offering enhanced services for identifying and managing diseases related to the skin, soft tissue, and bone of the lower extremity. The addition of Bako's molecular genetics testing further complements Fulgent's core business.
The combination of Fulgent Genetics and Bako Diagnostics is poised to deliver a more robust and specialized suite of diagnostic solutions. This integration is expected to enhance patient care by providing clinicians with a wider array of advanced testing options and actionable intelligence for disease diagnostics and management. The united entity will leverage Bako’s established clinical relationships and service infrastructure to accelerate growth and innovation in targeted diagnostic fields.